(19)

(11)

EP 4 770 647 A1

(12)

(43) Date of publication: 08.07.2026 Bulletin 2026/28 (21) Application number: 24861155.0 (22) Date of filing: 30.08.2024

(51) International Patent Classification (IPC):  A61K 31/5415(2006.01) A61K 31/4196(2006.01) A61K 47/06(2006.01) A61K 9/00(2006.01) A61K 47/02(2006.01) A61P 25/06(2006.01) (52) Cooperative Patent Classification (CPC): A61K 31/5415; A61K 31/4196   C-Sets: A61K 31/5415, A61K 2300/00; A61K 31/4196, A61K 2300/00; (86) International application number: PCT/US2024/044700 (87) International publication number: WO 2025/049927 (06.03.2025 Gazette 2025/10)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: GE KH MA MD TN (30) Priority: 31.08.2023 US 202363579833 P (71) Applicant: Axsome Therapeutics, Inc. New York, NY 10007 (US)	(72) Inventor: TABUTEAU, Herriot New York, 10007 (US) (74) Representative: Murgitroyd & Company  165-169 Scotland Street Glasgow G5 8PL Glasgow G5 8PL (GB)